Amgen Inc. (NASDAQ:AMGN) Shares Sold by Sowell Financial Services LLC

Sowell Financial Services LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,473 shares of the medical research company's stock after selling 1,036 shares during the quarter. Sowell Financial Services LLC's holdings in Amgen were worth $2,990,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Talbot Financial LLC grew its position in shares of Amgen by 5.6% in the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock valued at $11,153,000 after purchasing an additional 2,274 shares in the last quarter. Swiss National Bank boosted its stake in Amgen by 0.3% during the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company's stock worth $513,033,000 after buying an additional 5,500 shares during the last quarter. Asset Advisors Investment Management LLC grew its holdings in Amgen by 9.0% in the 3rd quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after buying an additional 2,954 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Amgen by 6.0% in the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock worth $204,659,000 after acquiring an additional 35,785 shares during the last quarter. Finally, Ascent Wealth Partners LLC raised its holdings in shares of Amgen by 0.7% during the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after acquiring an additional 64 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. William Blair reissued an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Redburn Partners reduced their price target on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Wolfe Research started coverage on Amgen in a research report on Friday, November 15th. They issued a "peer perform" rating for the company. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $314.04.

Amgen Stock Down 2.0 %

NASDAQ:AMGN traded down $6.39 during midday trading on Tuesday, reaching $320.97. The company had a trading volume of 1,732,625 shares, compared to its average volume of 2,548,861. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market capitalization of $172.43 billion, a price-to-earnings ratio of 42.58, a PEG ratio of 2.63 and a beta of 0.53. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock's fifty day simple moving average is $287.50 and its 200-day simple moving average is $299.50.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 2.97%. Amgen's dividend payout ratio (DPR) is currently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.